Pharnext completes patient enrolment in Phase lll trial of PXT3003 to treat CMT1A

French biopharmaceutical company Pharnext has completed the enrolment of patients for its new Phase lll PLEO-CMT trial of PXT3003 for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news